22nd Century Group, Inc. (XXII)

NCM – Real Time Price. Currency in USD

0.57

-0.01 (-2.49%)

Market open: May 13, 2026, 9:31 AM EDT

12.05.2026

22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review

FDA filing covers renewal applications for VLN® King and VLN® Menthol King, the first combusted cigarettes authorized as Modified Risk Tobacco Products, as 22nd Century advances its regulatory pathway for continued modified risk marketing status

09.05.2026

22nd Century Group, Inc. (XXII) Q1 2026 Earnings Call Prepared Remarks Transcript

07.05.2026

22nd Century Group Reports First Quarter 2026 Financial Results

Continues VLN ® Commercial Expansion with New Stores Selling Proprietary Branded VLN ® Products

04.05.2026

22nd Century Group to Announce First Quarter 2026 Results on May 7, 2026

MOCKSVILLE, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the only tobacco products company that has for 28 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction,, will host a webcast on Thursday, May 7, 2026, at 8:00 AM ET to discuss its 2026 first quarter results, which are to be reported in a press release at 6:00 AM ET the same day.

29.04.2026

22nd Century Group Shares 2026 Vision for VLN® Product Growth and Tobacco Harm Reduction Leadership

Chairman & CEO Larry Firestone Details 2026 Priorities and Shareholder Value Strategy MOCKSVILLE, N.C., April 29, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the only tobacco products company that has for 28 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today issued the following letter to stockholders from Lawrence Firestone, the Chairman and Chief Executive Officer of 22nd Century Group, Inc.: Dear Fellow Stockholders, As I reflect on the past year, I am proud of the progress our team has made to form the foundation of the future 22nd Century Group and position the company for long-term growth and success.

23.04.2026

22nd Century Group Expands Reduced Nicotine Platform Through New Testing Services Agreement with North Carolina State University

MOCKSVILLE, N.C., April 23, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a tobacco products company focused on nicotine reduction and plant biotechnology, today announced corporate updates regarding a new testing services agreement with North Carolina State University aimed at validating tobacco varieties featuring improved leaf quality and increased crop yields with the same low-nicotine content.

07.04.2026

22nd Century Advances Reduced Nicotine Product to Target Approximately Half of the ~$82 Billion U.S. Cigarette Market with 100mm VLN® Product Initiative

Company to Pursue Additional PMTA Submissions, Building on Its Status as the Only Holder of an FDA-Authorized Low Nicotine Combustible Cigarette Branded as VLN ® Products Expanded PMTA Portfolio and Licensing Strategy Designed to Address Wider Consumer Preference and Unlock Further Retail Penetration Opportunities MOCKSVILLE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced an update on the advancement of a 100mm VLN® reduced nicotine content cigarette.

Videos

No Data

There is no data to display

Press releases

12.05.2026

22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review

07.05.2026

22nd Century Group Reports First Quarter 2026 Financial Results

Continues VLN ® Commercial Expansion with New Stores Selling Proprietary Branded VLN ® Products

29.04.2026

22nd Century Group Shares 2026 Vision for VLN® Product Growth and Tobacco Harm Reduction Leadership

23.04.2026

22nd Century Group, Inc. (XXII)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

22nd Century Group, Inc. (XXII)

22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review

22nd Century Group, Inc. (XXII) Q1 2026 Earnings Call Prepared Remarks Transcript

22nd Century Group Reports First Quarter 2026 Financial Results

22nd Century Group to Announce First Quarter 2026 Results on May 7, 2026

22nd Century Group Shares 2026 Vision for VLN® Product Growth and Tobacco Harm Reduction Leadership

22nd Century Group Expands Reduced Nicotine Platform Through New Testing Services Agreement with North Carolina State University

22nd Century Advances Reduced Nicotine Product to Target Approximately Half of the ~$82 Billion U.S. Cigarette Market with 100mm VLN® Product Initiative

Videos

No Data

Press releases

22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review

22nd Century Group Reports First Quarter 2026 Financial Results

22nd Century Group Shares 2026 Vision for VLN® Product Growth and Tobacco Harm Reduction Leadership

22nd Century Group Expands Reduced Nicotine Platform Through New Testing Services Agreement with North Carolina State University

22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review

22nd Century Group, Inc. (XXII) Q1 2026 Earnings Call Prepared Remarks Transcript

22nd Century Group Reports First Quarter 2026 Financial Results

22nd Century Group to Announce First Quarter 2026 Results on May 7, 2026

22nd Century Group Shares 2026 Vision for VLN® Product Growth and Tobacco Harm Reduction Leadership

22nd Century Group Expands Reduced Nicotine Platform Through New Testing Services Agreement with North Carolina State University

22nd Century Advances Reduced Nicotine Product to Target Approximately Half of the ~$82 Billion U.S. Cigarette Market with 100mm VLN® Product Initiative

Videos

No Data

Press releases

22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review

22nd Century Group Reports First Quarter 2026 Financial Results

22nd Century Group Shares 2026 Vision for VLN® Product Growth and Tobacco Harm Reduction Leadership

22nd Century Group Expands Reduced Nicotine Platform Through New Testing Services Agreement with North Carolina State University

Search stocks

22nd Century Group, Inc. (XXII)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

22nd Century Group, Inc. (XXII)

22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review

22nd Century Group, Inc. (XXII) Q1 2026 Earnings Call Prepared Remarks Transcript

22nd Century Group Reports First Quarter 2026 Financial Results

22nd Century Group to Announce First Quarter 2026 Results on May 7, 2026

22nd Century Group Shares 2026 Vision for VLN® Product Growth and Tobacco Harm Reduction Leadership

22nd Century Group Expands Reduced Nicotine Platform Through New Testing Services Agreement with North Carolina State University

22nd Century Advances Reduced Nicotine Product to Target Approximately Half of the ~$82 Billion U.S. Cigarette Market with 100mm VLN® Product Initiative

Videos

No Data

Press releases

22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review

22nd Century Group Reports First Quarter 2026 Financial Results

22nd Century Group Shares 2026 Vision for VLN® Product Growth and Tobacco Harm Reduction Leadership

22nd Century Group Expands Reduced Nicotine Platform Through New Testing Services Agreement with North Carolina State University

22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review

22nd Century Group, Inc. (XXII) Q1 2026 Earnings Call Prepared Remarks Transcript

22nd Century Group Reports First Quarter 2026 Financial Results

22nd Century Group to Announce First Quarter 2026 Results on May 7, 2026

22nd Century Group Shares 2026 Vision for VLN® Product Growth and Tobacco Harm Reduction Leadership

22nd Century Group Expands Reduced Nicotine Platform Through New Testing Services Agreement with North Carolina State University

22nd Century Advances Reduced Nicotine Product to Target Approximately Half of the ~$82 Billion U.S. Cigarette Market with 100mm VLN® Product Initiative

Videos

No Data

Press releases

22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review

22nd Century Group Reports First Quarter 2026 Financial Results

22nd Century Group Shares 2026 Vision for VLN® Product Growth and Tobacco Harm Reduction Leadership

22nd Century Group Expands Reduced Nicotine Platform Through New Testing Services Agreement with North Carolina State University